Provided by Tiger Trade Technology Pte. Ltd.

TG Therapeutics

31.13
+0.34001.10%
Post-market: 30.60-0.5300-1.70%19:04 EST
Volume:1.19M
Turnover:36.97M
Market Cap:4.94B
PE:11.21
High:31.45
Open:30.56
Low:30.50
Close:30.79
52wk High:46.48
52wk Low:25.28
Shares:158.76M
Float Shares:148.00M
Volume Ratio:0.80
T/O Rate:0.80%
Dividend:- -
Dividend Rate:- -
EPS(TTM):2.78
EPS(LYR):0.1609
ROE:111.96%
ROA:7.97%
PB:8.14
PE(LYR):193.46

Loading ...

TG Therapeutics CEO to Join Evercore Healthcare Conference Fireside Chat

Reuters
·
Nov 28

Director Yann Echelard Reports Sale of TG Therapeutics Common Shares

Reuters
·
Nov 26

TG Therapeutics Makes 2025 Deloitte Technology Fast 500™ List of America’s Fastest-Growing Companies

GlobeNewswire
·
Nov 19

Perspective Therapeutics Chief Accounting Officer Jonathan Robert Hunt Acquires Common Shares

Reuters
·
Nov 17

TG Therapeutics to Join TD Cowen Immunology & Inflammation Summit

Reuters
·
Nov 11

TG Therapeutics (TGTX): Exploring Valuation After Raised Guidance and Strong Q3 Financial Results

Simply Wall St.
·
Nov 08

The Bull Case For TG Therapeutics (TGTX) Could Change Following Raised 2025 Outlook and Surging BRIUMVI Sales

Simply Wall St.
·
Nov 05

Stock Track | TG Therapeutics Plunges 5.08% as Profit Margin Drops and Valuation Concerns Emerge

Stock Track
·
Nov 04

Stock Track | TG Therapeutics Plunges 5.08% as Profit Margins Shrink and Valuation Concerns Mount

Stock Track
·
Nov 04

TG Therapeutics Reports Strong Q3 2025 Results

TIPRANKS
·
Nov 04

TG Therapeutics (TGTX): Profit Margin Drops to 13.3%, Challenging Premium Growth Narrative

Simply Wall St.
·
Nov 04

Positive Outlook for TG Therapeutics Driven by Strong Financial Performance and Strategic Initiatives

TIPRANKS
·
Nov 04

Positive Outlook on TG Therapeutics: Strong Revenue Growth and International Expansion Drive Buy Rating

TIPRANKS
·
Nov 04

TG Therapeutics Is Maintained at Overweight by JP Morgan

Dow Jones
·
Nov 04

TG Therapeutics Inc reports results for the quarter ended September 30 - Earnings Summary

Reuters
·
Nov 03

TG Therapeutics Shares Fall 9.3% After Q3 Results

THOMSON REUTERS
·
Nov 03

Stock Track | TG Therapeutics Plummets 5.66% Despite Strong Q3 Earnings and Raised Guidance

Stock Track
·
Nov 03

Stock Track | TG Therapeutics Plummets 5.66% Despite Strong Q3 Results and Raised Guidance

Stock Track
·
Nov 03

TG Therapeutics reports Q3 EPS $2.43, consensus 22c

TIPRANKS
·
Nov 03

TG Therapeutics raises FY25 revenue view $600M from $585M, consensus $588.12M

TIPRANKS
·
Nov 03